| Code | 4562B | ||||||||||
| MA number | 44/0257/15-S | ||||||||||
| Product Form: | plv ino 1x3,5 mg (liek.inj.skl.) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Glenmark Pharmaceuticals s.r.o., Czechia | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | glass vial | ||||||||||
| Route of admin.: | Subcutaneous and intravenous use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 24.06.2015 |
| SPC: |
SPC_Bortezomib Glenmark 3,5 mg_04.2025.pdf
|
| PIL: |
PIL_Bortezomib Glenmark 3,5 mg_04.2025.pdf
|
| Safety feature | Yes |
| Data update: | 22.07.2021 |
